Another ongoing phase I/II study is investigating combined nivolumab and the mTOR inhibitor ABI-009 in patients with chondrosarcoma and other advanced malignancies (ClinicalTrials.gov (accessed on 2 March 2021) Identifier: NCT03190174) [95]. This evidence concerns the gene MTOR and chondrosarcoma.